Teva Pharmaceutical Industries Ltd. — Director's Dealing 2022

Mar 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2022-03-04

Reporting Person: Sabag Mark (EVP, International Markets)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-04	Ordinary Shares	M	15920	—	Acquired	110523	Direct
2022-03-04	Ordinary Shares	M	43358	—	Acquired	153881	Direct
2022-03-05	Ordinary Shares	M	23764	—	Acquired	177645	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-04	Restricted Share Units	$	M	15920	Disposed		Ordinary Shares (15920)	Direct
2022-03-04	Restricted Share Units	$	M	43358	Disposed		Ordinary Shares (43358)	Direct
2022-03-04	Restricted Share Units	$	A	134048	Acquired		Ordinary Shares (134048)	Direct
2022-03-05	Restricted Share Units	$	M	23764	Disposed		Ordinary Shares (23764)	Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.

F3: Restricted share units were granted on March 4, 2019, with 15,920 having vested on each of March 4, 2021 and March 4, 2022 and 15,921 vesting on
March 4, 2023.

F4: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.

F5: Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.

F6: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765
vesting on March 5, 2025.